CBD and clopidogrel: a drug interaction worth taking seriously
This comes up in clinic more than you might expect. A patient on dual antiplatelet therapy after a coronary stent mentions they are also taking CBD oil. Most of the time it gets a polite nod and moves on. But the pharmacology here is worth understanding properly.
Clopidogrel is a prodrug. It does nothing until your liver activates it, and that activation depends almost entirely on a single enzyme: CYP2C19. Inhibit that enzyme and you potentially leave the patient with little to no antiplatelet cover.
CBD is a potent CYP2C19 inhibitor. In vitro studies show more than 50% inhibition at concentrations achievable with typical CBD doses. A 2023 clinical study (Bansal et al.) confirmed this in humans: a CBD-dominant extract produced a 207% increase in exposure of a CYP2C19 probe drug. That is not a theoretical interaction.
The gap in the evidence
No study has yet directly measured clopidogrel's active thiol metabolite in patients taking CBD. The thiol metabolite is the activated form that actually inhibits platelets. Without that data, the clinical risk remains an inference rather than a directly measured finding.
A Washington State University trial (NCT06692933) is currently investigating real-world CBD doses on clopidogrel pharmacokinetics. It should move this from plausible concern to evidence-based guidance.
How I approach it in practice
Until that data is available, I apply highest caution in patients with recently deployed drug-eluting stents and those known to be CYP2C19 intermediate or poor metabolisers. These are patients where inadequate platelet inhibition carries real consequences.
Prasugrel, ticagrelor, and aspirin do not rely on CYP2C19 activation. For patients who use CBD and need antiplatelet therapy, these are worth considering where clinically appropriate.
References
Bansal et al. Clin Pharmacol Ther 2023. CYP450 cannabinoid-drug interactions in healthy adults.
Greger et al. J Clin Pharmacol 2020. Cannabis interactions with anticoagulant and antiplatelet agents.
Healio Cardiology 2022. Cannabinoids and DDIs with CV medications.
NCT06692933. WSU trial: hemp product effects on clopidogrel PK/PD (enrolling).
Papakyriakopoulou et al. Br J Clin Pharmacol 2026. Cannabinoids and pharmacokinetic drug-drug interactions.
Comments & discussion
I welcome discussion on everything I write here. Medicine is rarely black and white, and botanical medicine shows even greater variance than most fields. I am genuinely open to other opinions and perspectives, and I read every comment.
Comments are approved before they appear, so there may be a short delay. Frank discussion of drugs, drug use, and differing clinical views is welcome. Hateful or abusive comments are not.